Pipeline
expanding the vaccine market is critical more than ever.
SK bioscience will continue to invest in vaccine R&D which will be the driving force of life science business
to secure the newest technology and expand a product portfolio.
(Year of 2017~2028, Unit: billion $)
- 0
- 20
- 40
- 60
- 80
- 100
- 120
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Source: BIS Research, Global Vaccine Market - Analysis and Forecast: 2018 to 2028, 2018.11, Recreated by Biotech Policy Research Center(BPRC)
The premium vaccine market is growing as the aging population is rapidly increasing.
The growing vaccine industry is resulting in better profitability, introduction of new R&D and manufacturing technologies, and new funding opportunities.
In recent years, the development of therapeutic vaccines which can treat currently existing diseases is also on the rise.
Vaccines are the most effective, efficient, and convenient to prevent and treat infectious diseases.Immunization through vaccination has become the most important public health policy in the world to prevent the outbreak of transboundary epidemics.
Approved| Basic Research / Preclinical | Phase I Clinical Trial | Phase II Clinical Trial | Phase III Clinical Trial | Commercialization | |
|---|---|---|---|---|---|
Cell Culture-based Influenza Quadrivalent |
 |
||||
|
|||||
|
|||||
|
|||||
COVID-19 Vaccine   |
Achieved BLA / of SKYCovione (KMFDS) |
||||
Combination Vaccine |
 |
||||
Universal Coronavirus Vaccine (Sarbecovirus)  |
|
||||
Nasal Spray*  |
|
||||
COVID-19 mRNA Vaccine |
|
||||
Next-Gen Pneumococcal Vaccine  |
 U.S. |
||||
RSV Vaccine |
|
||||
Cancer Immunotherapies, Obesity Vaccines, etc |
|
||||
Typhoid Conjugate Vaccine  |
Earned a biologics license for export |
||||
Cervical Cancer Vaccine (4-/10-valent) |
Phase I/II Clinical Trial |
||||
Rotavirus Vaccine |
 |
||||
iNTS² Vaccine* (Non-Typhoidal Salmonella) |
|
||||
Hepatitis A, Recombinant Herpes Zoster Vaccines, etc. |
|
||||
Etc. |
Development and global M&A in progress |
||||
1 Non-Replicating Rotavirus Vaccine
2 Invasive Non-Typhoidal Salmonella
* Collaboration Project